Cabaletta Bio Stock Performance
| CABA Stock | USD 2.29 0.42 22.46% |
The firm shows a Beta (market volatility) of 3.84, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cabaletta Bio will likely underperform. At this point, Cabaletta Bio has a negative expected return of -1.18%. Please make sure to confirm Cabaletta Bio's total risk alpha, potential upside, and the relationship between the standard deviation and maximum drawdown , to decide if Cabaletta Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cabaletta Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental drivers remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 8.53 | Five Day Return 8.99 | Year To Date Return (88.79) | Ten Year Return (75.15) | All Time Return (75.15) |
1 | Disposition of 258456 shares by 5am Ventures V, L.p. of Cabaletta Bio at 13.0 subject to Rule 16b-3 | 09/06/2024 |
2 | Disposition of 11000 shares by Gwendolyn Binder of Cabaletta Bio at 1.01 subject to Rule 16b-3 | 09/13/2024 |
3 | Lynx1 Capital Management LP Lowers Stock Position in Cabaletta Bio, Inc. - MarketBeat | 09/27/2024 |
4 | Acquisition by Nichtberger Steven of 333500 shares of Cabaletta Bio at 11.47 subject to Rule 16b-3 | 10/04/2024 |
5 | State Street Corps Strategic Reduction in Cabaletta Bio Inc Holdings | 10/17/2024 |
6 | Were Not Very Worried About Cabaletta Bios Cash Burn Rate - Yahoo Finance | 10/30/2024 |
7 | Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update | 11/14/2024 |
8 | Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 | 11/18/2024 |
9 | Acquisition by Simon Mark of 7000 shares of Cabaletta Bio at 0.9764 subject to Rule 16b-3 | 11/20/2024 |
10 | Cabaletta Bios SWOT analysis CAR-T pioneers stock faces pivotal moment - Investing.com | 11/21/2024 |
| Begin Period Cash Flow | 81.6 M |
Cabaletta |
Cabaletta Bio Relative Risk vs. Return Landscape
If you would invest 574.00 in Cabaletta Bio on August 28, 2024 and sell it today you would lose (345.00) from holding Cabaletta Bio or give up 60.1% of portfolio value over 90 days. Cabaletta Bio is currently does not generate positive expected returns and assumes 6.959% risk (volatility on return distribution) over the 90 days horizon. In different words, 61% of stocks are less volatile than Cabaletta, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cabaletta Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cabaletta Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cabaletta Bio, and traders can use it to determine the average amount a Cabaletta Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1703
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CABA |
Estimated Market Risk
| 6.96 actual daily | 61 61% of assets are less volatile |
Expected Return
| -1.18 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cabaletta Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cabaletta Bio by adding Cabaletta Bio to a well-diversified portfolio.
Cabaletta Bio Fundamentals Growth
Cabaletta Stock prices reflect investors' perceptions of the future prospects and financial health of Cabaletta Bio, and Cabaletta Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cabaletta Stock performance.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | (76.39 M) | ||||
| Shares Outstanding | 48.88 M | ||||
| Price To Earning | (3.33) X | ||||
| Price To Book | 0.52 X | ||||
| EBITDA | (73.23 M) | ||||
| Net Income | (67.67 M) | ||||
| Cash And Equivalents | 96.81 M | ||||
| Cash Per Share | 3.34 X | ||||
| Total Debt | 5.02 M | ||||
| Debt To Equity | (3.76) % | ||||
| Current Ratio | 15.22 X | ||||
| Book Value Per Share | 4.94 X | ||||
| Cash Flow From Operations | (53.55 M) | ||||
| Earnings Per Share | (2.16) X | ||||
| Market Capitalization | 111.93 M | ||||
| Total Asset | 253.65 M | ||||
| Retained Earnings | (233.24 M) | ||||
| Working Capital | 228.5 M | ||||
| Current Asset | 30.42 M | ||||
| Current Liabilities | 843.74 K | ||||
About Cabaletta Bio Performance
By analyzing Cabaletta Bio's fundamental ratios, stakeholders can gain valuable insights into Cabaletta Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cabaletta Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cabaletta Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.31) | (0.30) | |
| Return On Assets | (0.27) | (0.28) | |
| Return On Equity | (0.29) | (0.27) |
Things to note about Cabaletta Bio performance evaluation
Checking the ongoing alerts about Cabaletta Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cabaletta Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cabaletta Bio generated a negative expected return over the last 90 days | |
| Cabaletta Bio has high historical volatility and very poor performance | |
| Net Loss for the year was (67.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cabaletta Bio currently holds about 96.81 M in cash with (53.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cabaletta Bio has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Cabaletta Bios SWOT analysis CAR-T pioneers stock faces pivotal moment - Investing.com |
- Analyzing Cabaletta Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cabaletta Bio's stock is overvalued or undervalued compared to its peers.
- Examining Cabaletta Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cabaletta Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cabaletta Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cabaletta Bio's stock. These opinions can provide insight into Cabaletta Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cabaletta Stock analysis
When running Cabaletta Bio's price analysis, check to measure Cabaletta Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cabaletta Bio is operating at the current time. Most of Cabaletta Bio's value examination focuses on studying past and present price action to predict the probability of Cabaletta Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cabaletta Bio's price. Additionally, you may evaluate how the addition of Cabaletta Bio to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |